HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

olmesartan medoxomil (Votum)

Subscribe to New Research on olmesartan medoxomil

angiotensin II receptor antagonist; structure in first source

Also Known As:

Votum; Benicar; Olmetec; (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy-4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(tetrazol-5-yl)phenyl)phenyl)methylimidazol-5-carboxylate; Berlin-Chemie Brand of Olmesartan Medoxomil; CS 866; CS-866; Forest Brand of Olmesartan Medoxomil; Sankyo Brand of Olmesartan Medoxomil

Networked: 199 relevant articles (48 outcomes, 93 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 60
- 1-Ring Heterocyclic Compounds
  - Azoles: 413
    - Imidazoles: 107
      - olmesartan medoxomil: 199
    - Tetrazoles: 7
      - olmesartan medoxomil: 199

Experts

1.	Neutel, Joel M: 15 articles (12/2012 - 09/2002)
2.	Chrysant, Steven G: 13 articles (01/2014 - 06/2006)
3.	Kereiakes, Dean J: 13 articles (01/2014 - 01/2007)
4.	Dubiel, Robert: 12 articles (10/2012 - 01/2005)
5.	Oparil, Suzanne: 11 articles (01/2014 - 03/2007)
6.	Shojaee, Ali: 11 articles (04/2013 - 08/2009)
7.	Volpe, Massimo: 10 articles (01/2015 - 01/2009)
8.	Melino, Michael: 9 articles (01/2014 - 04/2008)
9.	Lee, James: 9 articles (01/2014 - 04/2008)
10.	Heyrman, Reinilde: 9 articles (07/2013 - 04/2008)

Related Diseases

1.	Hypertension (High Blood Pressure) 06/01/2001 - "Olmesartan medoxomil was safe and highly effective in lowering blood pressure in patients with mild to moderate essential hypertension in these studies." 01/01/2007 - "In an integrated analysis of seven US and European randomized, placebo-controlled, dose-ranging trials involving 3055 patients with stage 2 hypertension treated with olmesartan medoxomil 2.5-80 mg/day or placebo for 8 weeks, all olmesartan medoxomil doses were significantly more effective than placebo in lowering the mean DBP and mean SBP (p<or=0.001); notably, optimal BP-lowering efficacy was observed at higher dosages. " 10/01/2004 - "These facts suggest that olmesartan medoxomil would be beneficial for the treatment of hypertension and other end-organ diseases." 04/01/2003 - "Olmesartan medoxomil has been reported to be an effective agent for the treatment of hypertension. " 09/01/2002 - "Olmesartan medoxomil appears to be a safe and effective once-a-day treatment for hypertension."
2.	Atherosclerosis 01/01/2006 - "The efficacy of olmesartan medoxomil in reducing cardiovascular risk beyond BP reduction is currently being investigated in trials involving patients at high risk due to atherosclerosis or type 2 diabetes." 01/01/2006 - "Effect of olmesartan medoxomil on atherosclerosis: clinical implications of the emerging evidence." 04/19/2001 - "CS-866 was also tested in the Watanabe heritable hyperlipidemic (WHHL) rabbit model of atherosclerosis. " 01/01/2003 - "Additionally, animal studies indicate that olmesartan medoxomil may prove to be useful treatment for diabetic nephropathy, as well as atherosclerosis. " 04/19/2001 - "On the basis of results from animal models, CS-866 may be a useful treatment for diabetic nephropathy and atherosclerosis."
3.	Diabetic Nephropathies (Diabetic Nephropathy) 01/01/2005 - "Our study suggests that olmesartan medoxomil could be a valuable drug for the treatment of diabetic nephropathy by blocking the deleterious effects of AGEs." 10/01/2002 - "In electron microscopic analysis, loss of glomerular anionic sites, one of the causes of glomerular hyperpermeability in diabetic nephropathy, was found to be significantly prevented by CS-866 treatment. " 01/01/2003 - "Additionally, animal studies indicate that olmesartan medoxomil may prove to be useful treatment for diabetic nephropathy, as well as atherosclerosis. " 04/19/2001 - "On the basis of results from animal models, CS-866 may be a useful treatment for diabetic nephropathy and atherosclerosis." 04/19/2001 - "Given the proposed involvement of the renin-angiotensin system in diabetic nephropathy and atherosclerosis, we have tested CS-866 in animal models of these conditions. "
4.	Type 2 Diabetes Mellitus (MODY) 09/01/2011 - "Seated cuff blood pressure-lowering efficacy of an olmesartan medoxomil-based treatment regimen in patients with type 2 diabetes mellitus." 01/01/2010 - "An olmesartan medoxomil-based treatment algorithm is effective in achieving 24-hour BP control in patients with type 2 diabetes mellitus, regardless of age, race, sex, or severity of hypertension: subgroup analysis of the BENIFICIARY study." 05/01/2011 - "The safety and efficacy of an amlodipine/olmesartan medoxomil (OM)-based titration regimen was assessed in patients with type 2 diabetes mellitus and hypertension. " 01/01/2011 - "Effects of olmesartan medoxomil, an angiotensin II type 1 receptor antagonist, on plasma concentration of B-type natriuretic peptide, in hypertensive patients with type 2 diabetes mellitus: a preliminary, observational, open-label study." 07/01/2013 - "The efficacy and safety of 20-week treatment with an amlodipine (AML)/olmesartan medoxomil (OM)±hydrochlorothiazide (HCTZ) algorithm were assessed in patients with hypertension and type 2 diabetes mellitus (T2DM) who were uncontrolled by antihypertensive monotherapy. "
5.	Insulin Resistance 07/07/2008 - "We evaluated the role of the renin-angiotensin system in the pathogenesis of insulin resistance-associated, non-alcoholic steatohepatitis by using the angiotensin II type 1 receptor blocker olmesartan medoxomil in a diabetic rat model. " 04/01/2004 - "Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats." 11/01/2000 - "Temocapril and CS-866 lowered systolic blood pressure, improved insulin resistance, and reduced TNF-alpha in both skeletal muscles. " 04/01/2004 - "In this study we addressed this issue by investigating how a newly developed ARB, olmesartan medoxomil, influenced insulin sensitivity and TG metabolism in fructose-fed rats, a representative animal model of insulin resistance. "

Related Drugs and Biologics

1.	Amlodipine (Norvasc)
2.	Hydrochlorothiazide (Esidrix)
3.	Ramipril (Altace)
4.	Angiotensin Receptors (Angiotensin II Receptor)
5.	olmesartan
6.	Losartan (Cozaar)
7.	Angiotensin II
8.	Calcium Channels (Calcium Channel)
9.	irbesartan
10.	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)

Related Therapies and Procedures

1.	Sodium-Restricted Diet (Diet, Sodium Restricted)
2.	Oral Administration
3.	Peritoneal Dialysis
4.	Stents
5.	Drug-Eluting Stents